Article

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, 02114, USA.
Cancer cell (Impact Factor: 23.89). 02/2011; 19(2):165-7. DOI: 10.1016/j.ccr.2011.01.047
Source: PubMed

ABSTRACT A recent article in the New England Journal of Medicine by O'Shaughnessy et al. provides evidence that a treatment strategy aimed at inducing DNA damage with chemotherapy while simultaneously disabling repair using a PARP inhibitor might offer hope for patients with a treatment-refractory form of breast cancer.

Download full-text

Full-text

Available from: Leif W Ellisen, May 18, 2015
1 Follower
 · 
76 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This work proposes a fuzzy logic framework suitable for web page filtering. Web page classifiers are trained off-line using the directory structure of the Open Directory Project (http://dmoz.org/) and are available to the user through an appropriate interface. These classifiers are considered as fuzzy membership functions which determine the membership degree of a web page to each class. The user selects a number of classes and formulates logical rules combining the classifiers. Fuzzy logic operators are used in order to filter the results of a query according to the specified rule providing different views (orderings) of the search results to the user.
    Neural Network Applications in Electrical Engineering, 2002. NEUREL '02. 2002 6th Seminar on; 02/2002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The p53 family transcription factors p53, p63 and p73 make diverse contributions in development and cancer. Mutation or deletion of p53 is observed in the majority of human cancers. In contrast, p63 and p73 are not lost in cancer but mediate distinct genetic roles in normal and tumor-specific contexts: p73 promotes genome stability and mediates chemosensitivity, while p63 largely lacks these p53-like functions and instead promotes proliferation and cell survival. We recently uncovered a mechanism which maintains p63/p73 homeostasis within the epithelium through direct transcriptional regulation of microRNAs (miRs). We discovered that several of the top p63-regulated miRs target p73 for inhibition, including miR-193a-5p, a direct p63/p73 transcriptional target which is repressed by p63 and activated by p73 both in vitro and in vivo. The resulting feed-forward circuit involving p63, miR-193a-5p and p73 controls p73 levels, cell viability and DNA damage susceptibility in certain cancers including squamous cell carcinoma. Here, we discuss the evolutionary implications of this regulatory circuit, which may point to a general mechanism of miR-mediated cross-talk within transcription factor gene families. Additionally, we suggest that inducible chemoresistance mediated by this miR-dependent mechanism might be an attractive target for therapeutic intervention.
    Oncotarget 03/2011; 2(3):259-64. · 6.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recurrent fusions of ETS genes are considered driving mutations in a diverse array of cancers, including Ewing's sarcoma, acute myeloid leukemia, and prostate cancer. We investigate the mechanisms by which ETS fusions mediate their effects, and find that the product of the predominant ETS gene fusion, TMPRSS2:ERG, interacts in a DNA-independent manner with the enzyme poly (ADP-ribose) polymerase 1 (PARP1) and the catalytic subunit of DNA protein kinase (DNA-PKcs). ETS gene-mediated transcription and cell invasion require PARP1 and DNA-PKcs expression and activity. Importantly, pharmacological inhibition of PARP1 inhibits ETS-positive, but not ETS-negative, prostate cancer xenograft growth. Finally, overexpression of the TMPRSS2:ERG fusion induces DNA damage, which is potentiated by PARP1 inhibition in a manner similar to that of BRCA1/2 deficiency.
    Cancer cell 05/2011; 19(5):664-78. DOI:10.1016/j.ccr.2011.04.010 · 23.89 Impact Factor